Navigation Links
Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister
Date:7/9/2008

LEXINGTON, Mass., July 9 /PRNewswire/ -- Abt Bio-Pharma Solutions, Inc. (ABS), a global provider of integrated clinical, health economic, and strategic commercialization solutions, is pleased to announce that Nandini Hadker, an expert in marketing and business strategy, has been promoted to Executive Director and will oversee ABS' strategic commercialization practice, succeeding Susan Windham-Bannister, who has been appointed President & CEO of the Massachusetts Life Sciences Center (MLSC).

Dr. Windham-Bannister has worked with many biopharma companies and other health products/service providers during her more than 30 years with ABS and Abt Associates. The capabilities and relationships developed during her years with Abt Associates make Dr. Windham-Bannister uniquely qualified to guide the Center's implementation of Governor Deval Patrick's plan to secure Massachusetts' position as a global leader in life sciences research and development.

"With [the Massachusetts Life Sciences] initiative we take our rightful place as a global leader in the life sciences," said Governor Patrick. "There is no place in the world with as great a concentration of life sciences talent, resources and vision as Massachusetts. With these resources -- and the collaboration and support of the industry, academia, business and government -- we are on our way to helping find new cures for diseases, creating new jobs, and positioning ourselves for long-term economic growth."

Ms. Hadker has worked closely with Dr. Windham-Bannister on the company's many high-profile engagements with Fortune 50 clients, advising them on new product development, pricing and brand management. In addition to methodological expertise, Ms. Hadker combines multi-industry expertise and business acumen to help clients identify, assess and quantify opportunities, navigate complex marketplaces, and successfully position themselves with their customers -- be they physicians, hospitals, patients or payors. Ms. Hadker has played a critical role in the development of the company's strategic commercialization practice and is also active as a member of the company's senior management team.

"We are delighted that Sue's knowledge of and commitment to the life sciences industry has been recognized in this manner, and expect her to make a great contribution to Governor Patrick's initiative," said Steven Fosburg, President of ABS. "Although we are sorry to lose her as a colleague, as members of the Massachusetts life sciences community we look forward to seeing the benefits of her efforts for many years to come. Here at ABS, we anticipate a seamless transition as Nandini takes over sole leadership of our commercial strategy practice. We expect great things from her, as the group is poised for significant growth in the coming year and Nandini is the right candidate to lead that effort."

Ms. Hadker holds a Masters in Economics from Boston University and her work has been published in numerous peer-reviewed, scientific healthcare journals including The Journal of Occupational and Environmental Medicine and Haemophelia. She has also been a featured speaker at many professional conferences, especially in the area of new product planning and pharmaceutical pricing.

The ABS team has provided integrated strategic, research, and communications services to the pharmaceutical, biotechnology, medical device, and diagnostics industries for more than 20 years. The company specializes in demonstrating the value, safety, and efficacy of health technologies through prospective studies such as registries and clinical trials as well as through analyses of retrospective data. ABS teams of senior, seasoned staff help sponsors develop their research agendas, successfully conduct their research programs, communicate the results in peer-reviewed journals, and, where appropriate, appear before regulatory authorities. Primary service offerings include registries and other late-phase clinical studies, marketing research and strategy, health economics and outcomes research, and biometrics. Previously known as Abt Associates Clinical Trials, the company was renamed Abt Bio-Pharma Solutions and established as a wholly owned subsidiary of Abt Associates in April 2008.


'/>"/>
SOURCE Abt Bio-Pharma Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
2. Sentry Enhances Offerings with Temperature-Controlled Custom Bio-Pharmaceutical Finishing Services
3. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
4. Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence
5. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
6. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
7. Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou
8. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
9. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
10. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... The ... fracture-specific plating options designed to address fractures of the distal tibia and fibula. ... The Acumed Ankle Plating System 3 is composed of seven plate families that ...
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the ... research that could lead to one good one. Surviving Mesothelioma has just posted an ... The team evaluated 98 mesothelioma patients who got a second kind of ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. ... the company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar ... FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Last week, ... for corporate executives and entrepreneurs, held The Future of San Diego Life Science event ... San Diego life science community attended the event with speakers Dr. Rich Heyman, former ...
Breaking Biology Technology:
(Date:3/18/2016)... , March 18, 2016 ... Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure ... & security companies in the border security market and the ... and Europe has led visiongain ... companies improved success. --> defence & security ...
(Date:3/15/2016)... ALBANY, New York , March 15, 2016 ... a new market report published by Transparency Market Research "Digital ... Growth, Trends and Forecast 2015 - 2023," the global digital ... at US$ 731.9 Mn in 2014 and is forecast to ... to 2023. Growth of micro, small and medium enterprises (MSMEs) ...
(Date:3/14/2016)... MELBOURNE, Florida , March 14, 2016 ... on the growing mobile commerce market, announces the airing of ... York channels starting the week of March 21 st . ... and CNBC, including its popular Squawk on the Street show. ... company focused on the growing mobile commerce market, announces the ...
Breaking Biology News(10 mins):